Why is O'Day still here? No matter what news they release the stock goes down. He has to be the reason. Maybe they paid him too much money for him to actually get anything good done. Why should he care. He and his heirs are set for generations to come. And for doing what?
RBC Rates GILD to outperform. Support your company or liquidate it. Life is too short to breed hate.
Bullish
s
Guys, check out (http://Achieverspot.tech). They have been crushing it lately while GILD barley does anything at all.
S
Let's see what type of paid pumping @jim does today..
S
As Gilead’s stock price gets blitzed after a series of pratfalls, why is Dan O’Day getting a small raise? In the mean time the shareholders are getting the shaft.
S
Even a Goldman Sachs upgrade can’t get the stock going. ODAY is a Horror
Bullish
I
This stock is true ray of light….gotta love stability it provides ❤️
S
61.16-0.62 (-1.00%) As of 09:51AM EDT. Market open. @jim Good morning GILD pump master.
B
Oncology sales increased by 60% year-over-year, driven by increased demand for Trodelvy and cell therapy products.
d
You never know Gilead might advance back into the 60s. Is there somebody interested in acquiring Gilead?
d
The stock wants to rise!! 67 is the next resistance
S
Remember the gap on the chart at $67.91 that needs to be filled. Also, the 100 day moving average which GILD tracks well, is $63.73. We get above those levels that would be very bullish. If O'Day would just get out of the way.........
W
FYI...Yescarta increased revenues 4Q to 1Q 16%. I expect that to increase substantially since the Maryland plant will be online. Tescarta sales were 10%. Trodelvy sales jumped 24% probably because it had a full Q of sales in the UK. Veklury holding steady at 1.4B and 1.5B. ETA for substantial growth year end 2022 or 2023 imo.
S
62.13 +1.57 (+2.60%)As of 03:41PM EDT. Market open. This is the result of all of @jim pumping Daniel up. Let’s see how long Daniel can keep it up!!
A
Looks like we are in a nice safe haven here. Great growth in their pipeline, as economy slows we will remain steady with a robust divy
S
FACT.. O'Day has been the CEO for over three years and GILD is lower today than the day he took over. If it was not for the gift of Remdesivir which by the way, CEO O'Day had absolutely nothing to do with it, GILD would be trading south of $52.00. This is a fact. The truth hurts Jimmy boy.
V
Announced that the company’s Board of Directors declared a quarterly dividend of $0.73 per share of common stock for the second quarter of 2022. The dividend is payable on June 29, 2022, to stockholders of record at the close of business on June 15, 2022. Future dividends will be subject to Board approval.
d
Earnings are great! Any other company and the stock would be up 30 percent.
Y
EPS $2.12 vs $1.81 expected. REV $6.6 vs $6.28 expected. Trodelvy sales increased 103% YoY. Cell therapy sales increased 43% YoY. Not bad at all.
to outperform. Support your company or liquidate it. Life is too short to breed hate.
As of 09:51AM EDT. Market open. @jim Good morning GILD pump master.
Tescarta sales were 10%.
Trodelvy sales jumped 24% probably because it had a full Q of sales in the UK.
Veklury holding steady at 1.4B and 1.5B.
ETA for substantial growth year end 2022 or 2023 imo.
+1.57 (+2.60%)As of 03:41PM EDT. Market open. This is the result of all of @jim pumping Daniel up. Let’s see how long Daniel can keep it up!!
REV $6.6 vs $6.28 expected.
Trodelvy sales increased 103% YoY.
Cell therapy sales increased 43% YoY.
Not bad at all.